item management s discussion and analysis of financial condition and results of operations results of operations fiscal year compared to fiscal year net revenues net revenues for the twelve month period ended october  were  as compared to  for the prior comparable period ended october   this represents a increase in net revenues 
on september   the company completed the sale of certain assets of its gencare division gencare to an unrelated third party 
during the eleven month period ending september   net revenues related to gencare was  or of the company s net revenues 
the number of patients serviced for the twelve month period ended october  was  which was an increase of over the same period in the number of patients processed by gencare during this same twelve month period was  net revenue per patient including gencare was for the period ending october  as compared to an increase of 
net revenue per patient excluding gencare was or a decrease in per patient revenues for the current twelve month period 
management can not project if these increases will continue  or if they do  at what rate 
however  management believes but cannot assure  that the fastest growing portion of the gencare assets were retained by the company 
cost of services cost of services increased from  for the twelve month period ended october  to  for the twelve month period ended october  this represents a increase in direct operating costs and is in line with the increase in net revenues 
gross profits gross revenues increased from  or of net revenues for the twelve month period ended october  to  or of net revenues for the twelve month period ended october   an increase of 
general and administrative expenses general and administrative expenses for the twelve month period ended october  were  as compared to  for the twelve month period ended october   an increase of  
the reserve for bad debt was increased by  in the period ended october   compared to the period ended october  when the increase in reserve for bad debt is factored out  general and administrative expenses would have increased by 
this compares favorably to an increase in net revenues for the period of 
interest expense interest expense increased from  during the twelve month period ending october  to  during the twelve month period ending october  this increase was caused by the company s increase in asset based borrowings and equipment leases for the eleven months ending september  on october   the company utilized  of the cash payment received upon closing the gencare sale to reduce its credit line with pnc bank 
net income the company had net income of  for the twelve months ended october  as compared to  for the twelve months ended october  two thirds of the increase in net income is attributable to the non recurring gain on the sale of certain assets of the company s gencare division 
fiscal year compared to fiscal year net revenues net revenues for the twelve month period ended october  were  as compared to  for the prior comparable period ended october   this represents an increase in net revenues 
however  due to record snowfalls in the new york metropolitan area and based on volume on non weather affected days  management estimates net revenues would have been  greater if the northeast had not experienced such severe weather 
the laboratory s patient count for the twelve month period ending october  increased by over the same period in net revenues per patient decreased from for the period ending october  to for the period ending october  this represents a reduction in reimbursement levels 
the company processed  patients during the period ended october  and estimates that revenues were reduced by approximately  due to the reduction of reimbursement levels from the prior period 
management cannot project if these decreases will continue  or if they do  at what rate 
during july  the company acquired certain assets and rights including the customer list related to sbcl s renal dialysis testing business 
while no revenues were generated by this acquisition during fiscal  and sbcl represented that its renal dialysis business was realizing approximately  in annual net revenues  management believes that the company may realize only approximately  in annual net revenues directly as a result of this acquisition 
cost of services cost of services increased from  for the twelve month period ended october  to  for the period ended october  this represents a increase in direct operating costs 
employee costs increased and represents of the overall increase in direct operating expenses 
during this period  direct staffing  increased by employees 
reagents and laboratory supplies increased by over the prior comparable period and is in line with the overall increase in the number of patients processed 
other cost of services for the twelve month period ended october  increased by over the comparable period ended october  this increase is attributable primarily to two factors  a increase in pick up and delivery expenses and a increase in reference laboratory fees  which is reflective of the complexity of the tests and the geographical area in which these patients are serviced 
gross profits gross profit increased from  for the twelve month period ended october  to  for the period ended october   an increase of  the company s gross profit margin decreased to for the twelve month period ended october  compared to for the period ended october  this decrease resulted from an increase in net revenues of only  which was impacted by a decrease in reimbursement levels  while direct expenses increased by 
the company believes this decrease was attributable to the adverse effect on revenues due to severe winter weather and a decrease in net revenues per patient 
general and administrative expenses general and administrative expenses for the twelve month period ended october  were  as compared to  for the period ended october   an increase of  
this increase is in line with the increase in net revenues 
interest expense interest expense increased from  during the twelve month period ending october  as compared to  during the twelve month period ending october  this increase was caused by the company s increase in asset based borrowings and equipment leases 
net income the company had net income of  for the twelve months ended october  as compared to  for the twelve months ended october  management believes the decrease in net income was attributable to the extreme winter weather and record snowfalls that the northeast experienced in december  january and february and the reduction in reimbursement rates experienced during the current twelve month period 
liquidity and capital resources for the fiscal year ended october  working capital as of october  was  as compared to  at october  an increase of  during the twelve month period 
the company had  in cash and certificates of deposits at october  however   represented restricted deposits 
the company utilized  in cash for operating activities 
to offset this use of cash the company raised  from the divestiture of its gencare product line  reduced its credit line borowing by  and repaid approximately  in existing debt 
the capital spending requirements for the company during is expected not to exceed  during fiscal  approximately  has been spent on capital improvements and approximately  in capital leases 
the company had current liabilities of  at october  the three largest items in this category are notes payable of  accounts payable of  and accrued salaries and commissions of containment of health care costs  including reimbursement for clinical laboratory services  has been a focus of ongoing governmental activity 
omnibus budget reconciliation legislation  designed to reconcile existing laws with reductions and reimbursement required by enactment of a congressional budget can adversely affect clinical laboratories by reducing medicare reimbursement for laboratory services 
in each of the omnibus budget reconciliation laws enacted in  and  medicare reimbursement of clinical laboratories was reduced from previously authorized levels 
none of the reductions enacted to date has had a material adverse effect on the company 
for many of the tests performed for medicare beneficiaries or medicaid recipients  laboratories are required to bill medicare or medicaid directly  and to accept medicare or medicaid reimbursement as payment in full 
a number of proposals for legislation or regulation are under discussion which could have the effect of substantially reducing medicare reimbursements for clinical laboratories 
depending upon the nature of regulatory action  if any  which is taken and the content of legislation  if any  which is adopted  the company could experience a significant decrease in revenues from medicare and medicaid  which could have a material adverse effect on the company 
the company is unable to predict  however  the extent to which such actions will be taken 
the company intends to capitalize on the current trend of consolidation in the clinical laboratory industry through acquisitions of other laboratories in its geographical region with significant customer lists 
purchase prices to acquire other laboratories may involve cash  notes  common stock  and or combinations thereof 
the company has a credit facility with pnc bank  na for  as of october    of this facility was being utilized 
in addition  the company had verbally renegotiated the convertible debt due to certain former owners of gencare that were due and payable on january  in the amount of approximately  these notes were fully paid in november  cash on hand  equity financing and additional borrowing capabilities are expected to be sufficient to meet anticipated operating requirements  debt repayments and provide funds for capital expenditures  excluding acquisitions for the foreseeable future 
for the fiscal year ended october  working capital as of october  was  as compared to  at october  a decrease of  during the twelve month period 
the company had  in cash and certificates of deposits at october  however   represented restricted deposits 
the company utilized  in cash for operating activities 
to offset this use of cash the company raised  in long term debt   in credit line borrowings and repaid approximately  in existing debt 
the capital spending requirements for the company during is expected not to exceed  during fiscal  approximately  has been spent on capital improvements 
the company had current liabilities of  at october  the three largest items in this category are notes payable of  accounts payable of  and current portion of long term debt of project the company is in the process of identifying those systems that require changes to accommodate the year it has identified four areas of concern 
they are the laboratory s operations and billing systems  the general accounting systems and the two systems outside of its control  one being the payor systems and the other being the vendor systems 
at the present time  it appears that the laboratory systems will require changes that translate into approximately  in costs 
the general accounting systems which are supplied by an outside vendor will cost the company less than  to convert and are scheduled for conversion during the second quarter of the current fiscal year 
the payor systems are being converted per instructions on the part of each payor ie medicare  medicaid  insurance companies  etc for example  electronic claims filing for medicare has been completed  while the company has been told not to make any changes for new jersey medicaid until it is notified to do so 
the final system of concern to the company is its suppliers 
once its general accounting is converted to accommodate the year  the company is confident that it will accept the input of all vendor invoices 
note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cuase the company s actual results in future periods to be materially different from any future performance suggested herein 
impact of inflation to date  inflation has not had a material effect on the company s operations 
new authoritative pronouncements the financial accounting standards board fasb issued statement of financial accounting standards no 
 earnings per share eps  and sfas no 
 disclosure of information about capital structure in february sfas no 
simplifies the earnings per share eps calculations required by accounting principles board apb opinion o 
 and related interpretations  by replacing the presentation of primary eps with a presentation of basic eps 
sfas no 
requires dual presentation of basic and diluted eps by entities with complex capital structures 
basic eps includes no dilution and is computed by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period 
diluted eps reflects the potential dilution of securities that could share in the earnings of an entity  similar to the fully diluted eps of apb opinion no 
sfas no 
is effective for financial statements issued for periods ending after december   including interim periods  earlier application is not permitted 
when adopted  sfas no 
will require restatement of al prior period eps data presented 
basic eps will be based on average common shares outstanding and diluted eps will include the effects of potential common stock  such as  options and warrants 
the company s basic eps as calculated under sfas no 
would have been 
for the year ended october  the company s diluted eps as calculated under sfas no 
would have been 
for the year ended october  sfas no 
does not change any previous disclosure requirements  but rather consolidates existing disclosure requirements for each of retrieval 
the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 reporting comprehensive income 
sfas no 
is effective for fiscal years beginning after december  earlier application is permitted 
reclassification of financial statements for earlier periods provided for comparative purposes is required 
the company is in the process of determining its preferred format 
the adoption of sfas no 
will have no impact on the company s consolidated results of operations  financial position or cash flows 
the fasb has issued sfas no 
 disclosures about segments of an enterprise and related information 
sfas no 
changes how operating segments are reported in annual financial statements issued to shareholders 
sfas no 
is effective for periods beginning after december   and comparative information for earlier years is to be restated 
sfas no 
need not be applied to interim financial statements in the initial year of its application 
the company is in the process of evaluating the disclosure requirements 
the adoption of sfas no 
will have no impact on the company s consolidated results of operations  financial position or cash flows 
item a 
quantitative and qualitative disclosure about market risk not applicable 

